|
|
|
|
These results suggest that early DBS reduces the need for and complexity of PD medications while providing long-term motor benefit over standard medical therapy. Further investigation is warranted, and the Food and Drug Administration has approved the conduct of a prospective, multicenter, and pivotal clinical trial of DBS in early-stage PD (IDEG050016). |
|